RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Impact Therapeutics (Nanjing) closed a $30 million Series C round led by Decheng Capital with participation by Lilly Asian Ventures, an existing investor. Impact is a clinical-stage biopharma developing best-in-class candidates for cancer and other serious diseases. Proceeds from the funding will be used for clinical development of Impact’s IMP4297, a potential best-in-class PARP inhibitor, and to advance Impact’s other programs developed from its DNA Damage Response discovery technology.
Source: China Biotoday
